{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff31507\deff0\stshfdbch31506\stshfloch31506\stshfhich31506\stshfbi31507\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fbidi \fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}
{\f3\fbidi \fdecor\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f10\fbidi \fdecor\fcharset77\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}
{\f42\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0004020202020204}Aptos;}{\f43\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0004020202020204}Aptos Display;}{\f52\fbidi \fmodern\fcharset0\fprq1{\*\panose 020b0609020204030204}Consolas;}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0004020202020204}Aptos Display;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0004020202020204}Aptos;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f79\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\f80\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\f82\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f83\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f84\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\f85\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f86\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f87\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f89\fbidi \fmodern\fcharset238\fprq1 Courier New CE;}
{\f90\fbidi \fmodern\fcharset204\fprq1 Courier New Cyr;}{\f92\fbidi \fmodern\fcharset161\fprq1 Courier New Greek;}{\f93\fbidi \fmodern\fcharset162\fprq1 Courier New Tur;}{\f94\fbidi \fmodern\fcharset177\fprq1 Courier New (Hebrew);}
{\f95\fbidi \fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f96\fbidi \fmodern\fcharset186\fprq1 Courier New Baltic;}{\f97\fbidi \fmodern\fcharset163\fprq1 Courier New (Vietnamese);}{\f99\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}
{\f100\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}{\f102\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f103\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f106\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}
{\f107\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}{\f109\fbidi \fswiss\fcharset238\fprq2 Aptos CE;}{\f110\fbidi \fswiss\fcharset204\fprq2 Aptos Cyr;}{\f112\fbidi \fswiss\fcharset161\fprq2 Aptos Greek;}
{\f113\fbidi \fswiss\fcharset162\fprq2 Aptos Tur;}{\f116\fbidi \fswiss\fcharset186\fprq2 Aptos Baltic;}{\f117\fbidi \fswiss\fcharset163\fprq2 Aptos (Vietnamese);}{\f119\fbidi \fswiss\fcharset238\fprq2 Aptos Display CE;}
{\f120\fbidi \fswiss\fcharset204\fprq2 Aptos Display Cyr;}{\f122\fbidi \fswiss\fcharset161\fprq2 Aptos Display Greek;}{\f123\fbidi \fswiss\fcharset162\fprq2 Aptos Display Tur;}{\f126\fbidi \fswiss\fcharset186\fprq2 Aptos Display Baltic;}
{\f127\fbidi \fswiss\fcharset163\fprq2 Aptos Display (Vietnamese);}{\f129\fbidi \fmodern\fcharset238\fprq1 Consolas CE;}{\f130\fbidi \fmodern\fcharset204\fprq1 Consolas Cyr;}{\f132\fbidi \fmodern\fcharset161\fprq1 Consolas Greek;}
{\f133\fbidi \fmodern\fcharset162\fprq1 Consolas Tur;}{\f136\fbidi \fmodern\fcharset186\fprq1 Consolas Baltic;}{\f137\fbidi \fmodern\fcharset163\fprq1 Consolas (Vietnamese);}{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Aptos Display CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Aptos Display Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Aptos Display Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Aptos Display Tur;}{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Aptos Display Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Aptos Display (Vietnamese);}
{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Aptos CE;}{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Aptos Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Aptos Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Aptos Tur;}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Aptos Baltic;}{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Aptos (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;
\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;
\caccentone\ctint255\cshade191\red15\green71\blue97;\ctextone\ctint166\cshade255\red89\green89\blue89;\ctextone\ctint216\cshade255\red39\green39\blue39;\caccentone\ctint255\cshade255\red21\green96\blue130;\red0\green112\blue32;\red144\green32\blue0;
\red64\green160\blue112;\red136\green0\blue0;\red64\green112\blue160;\red187\green102\blue136;\red96\green160\blue176;\red186\green33\blue33;\red6\green40\blue126;\red25\green23\blue124;\red102\green102\blue102;\red188\green122\blue0;
\red125\green144\blue41;}{\*\defchp \f31506\fs24\lang9\langfe1033\langnp9 }{\*\defpap \ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{
\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{
\s1\ql \li0\ri0\sb360\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel0\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs40\alang1025 \ltrch\fcs0 
\fs40\cf19\lang9\langfe1033\loch\f31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink27 \sqformat \spriority9 heading 1;}{
\s2\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs32\alang1025 \ltrch\fcs0 
\fs32\cf19\lang9\langfe1033\loch\f31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink28 \ssemihidden \sunhideused \sqformat \spriority9 heading 2;}{
\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink29 \ssemihidden \sunhideused \sqformat \spriority9 heading 3;}{
\s4\ql \li0\ri0\sb80\sa40\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel3\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \ai\af31503\afs24\alang1025 \ltrch\fcs0 
\i\fs24\cf19\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink30 \ssemihidden \sunhideused \sqformat \spriority9 heading 4;}{
\s5\ql \li0\ri0\sb80\sa40\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel4\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs24\alang1025 \ltrch\fcs0 
\fs24\cf19\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink31 \ssemihidden \sunhideused \sqformat \spriority9 heading 5;}{
\s6\ql \li0\ri0\sb40\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel5\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \ai\af31503\afs24\alang1025 \ltrch\fcs0 
\i\fs24\cf20\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink32 \ssemihidden \sunhideused \sqformat \spriority9 heading 6;}{
\s7\ql \li0\ri0\sb40\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel6\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs24\alang1025 \ltrch\fcs0 
\fs24\cf20\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink33 \ssemihidden \sunhideused \sqformat \spriority9 heading 7;}{
\s8\ql \li0\ri0\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel7\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \ai\af31503\afs24\alang1025 \ltrch\fcs0 
\i\fs24\cf21\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink34 \ssemihidden \sunhideused \sqformat \spriority9 heading 8;}{
\s9\ql \li0\ri0\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel8\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs24\alang1025 \ltrch\fcs0 
\fs24\cf21\lang9\langfe1033\loch\f31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink35 \ssemihidden \sunhideused \sqformat \spriority9 heading 9;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 
Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \sqformat \spriority0 
Body Text;}{\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 
\sbasedon15 \snext15 \sqformat \spriority0 First Paragraph;}{\s17\ql \li0\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 
\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon15 \snext17 \sqformat \spriority0 Compact;}{\s18\qc \li0\ri0\sa80\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\contextualspace \rtlch\fcs1 
\af31503\afs56\alang1025 \ltrch\fcs0 \fs56\expnd-2\expndtw-10\lang9\langfe1033\kerning28\loch\f31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \slink19 \sqformat \spriority10 Title;}{\*\cs19 \additive \rtlch\fcs1 
\af31503\afs56 \ltrch\fcs0 \fs56\expnd-2\expndtw-10\kerning28\loch\f31502\hich\af31502\dbch\af31501 \sbasedon10 \slink18 \spriority10 Title Char;}{
\s20\qc \li0\ri0\sa80\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ilvl1\adjustright\rin0\lin0\itap0\contextualspace \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\expnd3\expndtw15\lang9\langfe1033\kerning28\loch\f31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 \sbasedon18 \snext15 \slink21 \sqformat \spriority11 Subtitle;}{\*\cs21 \additive \rtlch\fcs1 \af31503\afs28 \ltrch\fcs0 
\fs28\expnd3\expndtw15\cf20\dbch\af31501 \sbasedon10 \slink20 \spriority11 Subtitle Char;}{\s22\qc \li0\ri0\sa200\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 
\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \snext15 \sqformat \spriority0 Author;}{\s23\qc \li0\ri0\sa200\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 
\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \snext15 \sqformat \spriority0 Date;}{\s24\qc \li0\ri0\sb300\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs20\alang1025 \ltrch\fcs0 
\b\f31506\fs20\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext25 \sqformat \spriority0 Abstract Title;}{\s25\ql \li0\ri0\sb100\sa300\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs20\alang1025 \ltrch\fcs0 \f31506\fs20\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext15 \sqformat \spriority0 Abstract;}{\s26\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext26 \sqformat \spriority0 Bibliography;}{\*\cs27 \additive \rtlch\fcs1 \af31503\afs40 \ltrch\fcs0 
\fs40\cf19\loch\f31502\hich\af31502\dbch\af31501 \sbasedon10 \slink1 \spriority9 Heading 1 Char;}{\*\cs28 \additive \rtlch\fcs1 \af31503\afs32 \ltrch\fcs0 \fs32\cf19\loch\f31502\hich\af31502\dbch\af31501 \sbasedon10 \slink2 \ssemihidden \spriority9 
Heading 2 Char;}{\*\cs29 \additive \rtlch\fcs1 \af31503\afs28 \ltrch\fcs0 \fs28\cf19\dbch\af31501 \sbasedon10 \slink3 \ssemihidden \spriority9 Heading 3 Char;}{\*\cs30 \additive \rtlch\fcs1 \ai\af31503 \ltrch\fcs0 \i\cf19\dbch\af31501 
\sbasedon10 \slink4 \ssemihidden \spriority9 Heading 4 Char;}{\*\cs31 \additive \rtlch\fcs1 \af31503 \ltrch\fcs0 \cf19\dbch\af31501 \sbasedon10 \slink5 \ssemihidden \spriority9 Heading 5 Char;}{\*\cs32 \additive \rtlch\fcs1 \ai\af31503 \ltrch\fcs0 
\i\cf20\dbch\af31501 \sbasedon10 \slink6 \ssemihidden \spriority9 Heading 6 Char;}{\*\cs33 \additive \rtlch\fcs1 \af31503 \ltrch\fcs0 \cf20\dbch\af31501 \sbasedon10 \slink7 \ssemihidden \spriority9 Heading 7 Char;}{\*\cs34 \additive \rtlch\fcs1 
\ai\af31503 \ltrch\fcs0 \i\cf21\dbch\af31501 \sbasedon10 \slink8 \ssemihidden \spriority9 Heading 8 Char;}{\*\cs35 \additive \rtlch\fcs1 \af31503 \ltrch\fcs0 \cf21\dbch\af31501 \sbasedon10 \slink9 \ssemihidden \spriority9 Heading 9 Char;}{
\s36\ql \li480\ri480\sb100\sa100\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin480\lin480\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 
\sbasedon15 \snext15 \sunhideused \sqformat \spriority9 Block Text;}{\s37\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 
\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext37 \sunhideused \sqformat \spriority9 footnote text;}{\s38\ql \li480\ri480\sb100\sa100\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin480\lin480\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon37 \snext37 \sunhideused \sqformat \spriority9 Footnote Block Text;}{\*
\ts39\tsrowd\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \snext39 \ssemihidden \sunhideused \sqformat \spriority0 
Table;}{\*\ts39\tsrowd\trql\tsvertalb\tsbrdrb\brdrs \rtlch\fcs1 \af31507 \ltrch\fcs0 \tscfirstrow Table;}{\s40\ql \li0\ri0\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 
\ltrch\fcs0 \b\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext41 \spriority0 Definition Term;}{\s41\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 
\ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext41 \spriority0 Definition;}{\s42\ql \li0\ri0\sa120\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 
\ltrch\fcs0 \i\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext42 \slink47 \spriority0 caption;}{\s43\ql \li0\ri0\sa120\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \i\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon42 \snext43 \spriority0 Table Caption;}{\s44\ql \li0\ri0\sa120\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \i\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon42 \snext44 \spriority0 Image Caption;}{\s45\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext45 \spriority0 Figure;}{\s46\ql \li0\ri0\sa200\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon45 \snext46 \spriority0 Captioned Figure;}{\*\cs47 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon10 \slink42 \spriority0 Caption Char;}{\*\cs48 
\additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22 \sbasedon47 \slink53 \spriority0 Verbatim Char;}{\*\cs49 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon47 \spriority0 Section Number;}{\*\cs50 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \super 
\sbasedon47 \spriority0 footnote reference;}{\*\cs51 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \cf22 \sbasedon47 \spriority0 Hyperlink;}{\s52\ql \li0\ri0\sb240\sa80\sl259\slmult1
\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs40\alang1025 \ltrch\fcs0 \fs40\cf19\lang9\langfe1033\loch\f31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 
\sbasedon1 \snext15 \sunhideused \sqformat \spriority39 TOC Heading;}{\s53\ql \li0\ri0\sa200\widctlpar\wrapdefault\nowwrap\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 
\f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 \sbasedon0 \snext53 \slink48 \spriority0 Source Code;}{\*\cs54 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\f52\fs22\cf23 \sbasedon48 \spriority0 KeywordTok;}{\*\cs55 \additive \rtlch\fcs1 \af0 
\ltrch\fcs0 \f52\fs22\cf24 \sbasedon48 \spriority0 DataTypeTok;}{\*\cs56 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf25 \sbasedon48 \spriority0 DecValTok;}{\*\cs57 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf25 \sbasedon48 \spriority0 
BaseNTok;}{\*\cs58 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf25 \sbasedon48 \spriority0 FloatTok;}{\*\cs59 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf26 \sbasedon48 \spriority0 ConstantTok;}{\*\cs60 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 
\f52\fs22\cf27 \sbasedon48 \spriority0 CharTok;}{\*\cs61 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf27 \sbasedon48 \spriority0 SpecialCharTok;}{\*\cs62 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf27 \sbasedon48 \spriority0 StringTok;}{\*
\cs63 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf27 \sbasedon48 \spriority0 VerbatimStringTok;}{\*\cs64 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf28 \sbasedon48 \spriority0 SpecialStringTok;}{\*\cs65 \additive \rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f52\fs22\cf11 \sbasedon48 \spriority0 ImportTok;}{\*\cs66 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \i\f52\fs22\cf29 \sbasedon48 \spriority0 CommentTok;}{\*\cs67 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \i\f52\fs22\cf30 \sbasedon48 \spriority0 
DocumentationTok;}{\*\cs68 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\i\f52\fs22\cf29 \sbasedon48 \spriority0 AnnotationTok;}{\*\cs69 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\i\f52\fs22\cf29 \sbasedon48 \spriority0 CommentVarTok;}{\*\cs70 \additive 
\rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf23 \sbasedon48 \spriority0 OtherTok;}{\*\cs71 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf31 \sbasedon48 \spriority0 FunctionTok;}{\*\cs72 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf32 
\sbasedon48 \spriority0 VariableTok;}{\*\cs73 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\f52\fs22\cf23 \sbasedon48 \spriority0 ControlFlowTok;}{\*\cs74 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf33 \sbasedon48 \spriority0 OperatorTok;}{\*\cs75 
\additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf11 \sbasedon48 \spriority0 BuiltInTok;}{\*\cs76 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22 \sbasedon48 \spriority0 ExtensionTok;}{\*\cs77 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf34 
\sbasedon48 \spriority0 PreprocessorTok;}{\*\cs78 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22\cf35 \sbasedon48 \spriority0 AttributeTok;}{\*\cs79 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22 \sbasedon48 \spriority0 RegionMarkerTok;}{\*\cs80 
\additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\i\f52\fs22\cf29 \sbasedon48 \spriority0 InformationTok;}{\*\cs81 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\i\f52\fs22\cf29 \sbasedon48 \spriority0 WarningTok;}{\*\cs82 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f52\fs22\cf6 \sbasedon48 \spriority0 AlertTok;}{\*\cs83 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \b\f52\fs22\cf6 \sbasedon48 \spriority0 ErrorTok;}{\*\cs84 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \f52\fs22 \sbasedon48 \spriority0 NormalTok;}}{\*\listtable
{\list\listtemplateid-94371288{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0
\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext
\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li2880\lin2880 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0
\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 
\fi-360\li5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01 ;}{\levelnumbers;}\hres0\chhres0 \fi-360\li6480\lin6480 }{\listname ;}\listid43408}{\list\listtemplateid-1987154806{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0
\levelstartat0\levelspace0\levelindent0{\leveltext\'01\u-3913 _;}{\levelnumbers;}\f3\fbias0\hres0\chhres0 \fi-360\li720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext
\'01o;}{\levelnumbers;}\f2\fbias0\hres0\chhres0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01\u-3929 _;}{\levelnumbers;}\f10\fbias0\hres0\chhres0 
\fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01\u-3913 _;}{\levelnumbers;}\f3\fbias0\hres0\chhres0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23
\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01o;}{\levelnumbers;}\f2\fbias0\hres0\chhres0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0
\levelindent0{\leveltext\'01\u-3929 _;}{\levelnumbers;}\f10\fbias0\hres0\chhres0 \fi-360\li4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01\u-3913 _;}{\levelnumbers;}
\f3\fbias0\hres0\chhres0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01o;}{\levelnumbers;}\f2\fbias0\hres0\chhres0 \fi-360\li5760\lin5760 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\'01\u-3929 _;}{\levelnumbers;}\f10\fbias0\hres0\chhres0 \fi-360\li6480\lin6480 }{\listname ;}\listid43409}{\list\listtemplateid1848827062{\listlevel
\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'00.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li720\lin720 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0
\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc2\levelnfcn2\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0
\levelindent0{\leveltext\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext
\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'04.;}{\levelnumbers\'01;}
\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc2\levelnfcn2\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 
\hres0\chhres0 \fi-360\li4320\lin4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li5040\lin5040 }
{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc2\levelnfcn2\leveljc0
\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \hres0\chhres0 \fi-360\li6480\lin6480 }{\listname ;}\listid11112961}}{\*\listoverridetable{\listoverride\listid43408
\listoverridecount0\ls1}{\listoverride\listid11112961\listoverridecount9{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}
{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}{\lfolevel\listoverridestartat\levelstartat1}\ls2}
{\listoverride\listid43409\listoverridecount0\ls3}{\listoverride\listid43409\listoverridecount0\ls4}{\listoverride\listid43409\listoverridecount0\ls5}}{\*\rsidtbl \rsid145594\rsid878590\rsid5777772\rsid9776367\rsid15230765}{\mmathPr\mmathFont34\mbrkBin0
\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Resnick, Adam C}{\operator Resnick, Adam C}{\creatim\yr2025\mo11\dy9\hr10\min9}{\revtim\yr2025\mo11\dy9\hr10\min9}{\version2}{\edmins0}
{\nofpages1}{\nofwords7695}{\nofchars43867}{\nofcharsws51460}{\vern4757}}{\*\userprops {\propname generator}\proptype30{\staticval ChatGPT Deep Research}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\ftnrestart\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1
\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace360\dgvspace360\dghorigin600\dgvorigin0\dghshow0\dgvshow0
\jexpand\viewkind5\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\rsidroot878590\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 0400}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}
{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}
{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\pard\plain \ltrpar
\s1\ql \li0\ri0\sb360\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel0\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs40\alang1025 \ltrch\fcs0 
\fs40\cf19\lang9\langfe1033\loch\af31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart header}{\*\bkmkstart Xf38c977c61f036247de3444d788f9a19e1e08b1}{\*\bkmkstart content}
\hich\af31502\dbch\af31501\loch\f31502 Pediatric Oncology Treatment Protocols Reference}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 Below is a }{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid15230765 reference guide to be used in conjunction with }{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  table }{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid15230765\charrsid15230765 CBTN_REDCAP_Protocols.csv}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid15230765\charrsid15230765  }{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
(CSV format) detailing each protocol (from the provided REDCap list) with structured information. The table includes the protocol ID, specific arm (if applicable), key treatment components (chemotherapy agents, radiation modality, targeted/immunotherapy),
 the treatment sequence/phases, dosing or radiation specifics when available, and notes (including patient eligibility or context). Citations to authoritative sources are provided for verification.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Note:}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Some entries in the REDCap list correspond to biology or pilot studies (e.g., ANBL00B1 is a biology study, ANBL00P1 a pilot study) rather than specific treatment regimens; those are included with minimal description. For brevity, similar protocols or arm
s are grouped, and dosing is summarized. Full protocol details can be found in referenced clinical trial documents or publications.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s2\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs32\alang1025 \ltrch\fcs0 
\fs32\cf19\lang9\langfe1033\loch\af31502\hich\af31502\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart reference-guide-and-inference-guidelines}\hich\af31502\dbch\af31501\loch\f31502 
Reference Guide and Inference Guidelines}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 
This section provides a narrative overview of these pediatric oncology protocols and guidance for inferring protocol enrollment from treatment details, even if not explicitly stated in a clinical note. The protocols are organized by disease category, and 
key identifying features of their regimens are highlighted. By recognizing drug combinations, dosing schedules, and sequence of therapy, one can often deduce if a patient was treated per a specific protocol.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }\pard\plain \ltrpar\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\af31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart X2a83c179a0864b78f68df3012102e0a5b4b2856}\hich\af31506\dbch\af31501\loch\f31506 
Leukemia/Lymphoma Protocols (COG AALL, ANHL, etc.)}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Acute Lymphoblastic Leukemia (ALL)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG AALL0434}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 for T-cell ALL: - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
: Multi-phase chemotherapy (Induction, Consolidation, Intensification, Maintenance) using vincristine, anthracyclines, corticosteroids, cytarabine, cyclophosphamide, methotrexate, 6-mercaptopurine, and asparaginase. T-ALL protocols often include early cra
nial radiation for CNS-positive disease and nelarabine for T-cell ALL}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric" \\
l ":~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [3]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/" \\l ":~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [4]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues
}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Presence of nelarabine in a pediatric ALL regimen strongly suggests AALL0434 or successor T-ALL trials}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric" \\l ":~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [3]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
. Cranial irradiation (12\endash 18 Gy) during consolidation for CNS3 patients also aligns with AALL0434}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/" \\l ":~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [4]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . If a patient\rquote s chemo orders follow an \'93ABFM\'94
 backbone (Adriamycin, high-dose MTX or Capizzi MTX, etc.) with or without nelarabine, it likely maps to this trial.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Non-Hodgkin Lymphoma (NHL)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 CCG-A5971 (lymphoblastic lymphoma)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  and }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 ANHL0131 (B-cell NHL)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : BFM-based intensive chemotherapy for lymphoblastic lymphoma (similar to ALL therapy)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\
l ":~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [79]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , or short intense courses (COPADM, CYM) for B-cell NHL (French LMB protocol). - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
: For lymphoblastic lymphoma, ALL-like treatment (vincristine, prednisone, doxorubicin, PEG-asparaginase, cyclophosphamide) suggests CCG-A5971 or similar. Presence of high-dose methotrexate and CNS prophylaxis without overt leukemia diagnosis indicates ly
mphoma protocol. If a note mentions \'93BFM regimen B\'94 or intrathecal therapy with no leukemia, likely a lymphoma trial}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [79]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . For B-NHL (e.g. Burkitt), regimens named \'93FAB/LMB\'94
 or drugs like high-dose cyclophosphamide, methotrexate (3\endash 8 g/m\'b2), and cytarabine in short cycles indicate an LMB-based trial (such as ANHL1131 or predecessor ANHL0131, especially if rituximab was added in later trials).}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hodgkin Lymphoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG AAHodgkin trials}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
: ABVD or OEPA-COPDac chemotherapy and involved-field radiation for advanced disease; abbreviated chemo (e.g., vincristine + vinblastine + prednisone + doxorubicin) for low risk. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Mention of ABVD agents in a pediatric context (dosed over multiple cycles) and low-dose IF-RT (~15\endash 
25 Gy) suggests a COG Hodgkin protocol such as AAHOD0031 or predecessor. Additional vinblastine in consolidation (as in ANHL0131}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=164%20,ANHL0131%3A%20Experimental%3A%20Consolidation%20with%20Vinblastine" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [67]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 ) would specifically point to that experimental arm.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }\pard\plain \ltrpar\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\af31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart Xc9a637d338794c1a78ab22ec21473a54196862e}{\*\bkmkend X2a83c179a0864b78f68df3012102e0a5b4b2856}
\hich\af31506\dbch\af31501\loch\f31506 CNS Tumor Protocols (Medulloblastoma/PNET, Ependymoma, High-Grade Glioma, DIPG)}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Standard-Risk Medulloblastoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (age \u8805\'5f3, M0): Protocols like }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ACNS0331}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  and earlier CCG/POG trials: - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Surgery \u8594\'5f CSI ~23.4 Gy with weekly vincristine \u8594\'5f
 posterior fossa or tumor-bed boost (~54\endash 55.8 Gy)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\
l ":~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [6]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \u8594\'5f 6\endash 9 cycles of platinum-based adjuvant chemotherapy (e.g., cisplatin, CCNU, vincristine)}{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [5]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 . - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : A child age 3\endash 
8 receiving exactly 23.4 Gy CSI (lower than older standard 36 Gy) followed by monthly cycles of cisplatin, lomustine, and vincristine indicates an average-risk medulloblastoma protocol}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [5]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . If the note mentions }{
\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 reduced-dose craniospinal irradiation}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  and maintenance chemo, it likely aligns with ACNS0331 or CCG-9961. Involvement of an \'93IFRT vs PFRT\'94
 comparison or cognitive evaluations suggests ACNS0331}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\
l ":~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [6]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 High-Risk Medulloblastoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (metastatic or subtotal resection): Protocols like }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ACNS0332}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Surgery \u8594\'5f CSI 36 Gy (full dose) + concurrent }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 carboplatin}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (radiosensitizer in experimental arm)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [11]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \u8594\'5f
 intensive adjuvant chemo (often alternating cycles of cisplatin/vincristine/cyclophosphamide and high-dose methotrexate or cyclophosphamide/etoposide) \u8594\'5f \'b1 biologic agent (isotretinoin was tested)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [15]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 
\ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Documentation of carboplatin given }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 during radiation}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  is a strong pointer to ACNS0332}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\
l ":~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [11]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (or St. Jude trial SJMB03 if done off-study, but COG is more likely). Additionally, maintenance }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 isotretinoin (13-cis-retinoic acid)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  for ~6\endash 12 months in a medulloblastoma patient is a distinctive feature of ACNS0332 arms C/D}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [15]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . If a patient\rquote 
s regimen includes 6 cycles of cisplatin, cyclophosphamide, vincristine, followed by isotretinoin, that essentially confirms ACNS0332 participation}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [5]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Infant Brain Tumors (Medulloblastoma/PNET <3 years)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Trials like }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ACNS0334}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 , }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 Head Start II/III}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 SJYC07}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Omit upfront radiation; use intensive chemo to delay/avoid RT. Often }{\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 induction chemotherapy}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (multiple cycles including high-dose methotrexate in some protocols) followed by }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
myeloablative chemotherapy with stem cell transplant}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Infants treated with }{
\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 high-dose methotrexate}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  as part of initial therapy (with leucovorin rescue) followed by stem cell transplant likely were
 on ACNS0334 (if on a COG trial)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\
l ":~:text=ARM%20II%3A%20Patients%20receive%20vincristine,for%203%20courses%20in%20the" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [31]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  or SJYC07. If no methotrexate but multiple induction cycles and then a single or tandem transplant, it suggests Head Start protocol. For example, }{
\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Head Start}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  is indicated by 5 drug induction (vincristine, cisplatin, etoposide, cyclophosphamide, \'b1 methotrexate) and }{\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 3 sequential transplants}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (Head Start II) or a single transplant (Head Start III). A note of \'93thiotepa/carboplatin transplant\'94
 in a toddler without radiation implies Head Start or ACNS0334 consolidation}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\
l ":~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [74]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . Also, mention of an }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
autologous transplant in a patient under 3 with a brain tumor}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  strongly signals an infant brain tumor trial (since standard medulloblastoma therapy does not use transplant except in trials).}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Ependymoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Trials like }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ACNS0831}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : - }
{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Maximal surgical resection \u8594\'5f }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Conformal radiation (usually 54
\endash 59.4 Gy)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . The role of chemo is controversial; ACNS0831 tested }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
post-RT maintenance chemo (VCEC: vincristine, cisplatin, etoposide, cyclophosphamide)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=I,VCEC" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [57]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  vs observation. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 : If a note indicates a child with ependymoma received radiation followed by }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 four cycles of vincristine, cisplatin, cyclophosphamide, etoposide}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 , it suggests they were on ACNS0831 and randomized to chemotherapy}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=I,VCEC" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [57]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
. Conversely, radiation with no chemo (beyond possible induction attempts) suggests either ACNS0831 observation arm or treatment off-trial (since previous standards didn\rquote 
t use adjuvant chemo after radiation). The timing of radiation is also telling: ACNS0831 mandated starting RT within 3\endash 8 weeks of surgery}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.sciencedirect.com/science/article/pii/S245210942100049X" \\l ":~:text=Effect%20of%20Postoperative%20Radiation%20Therapy,The%20purpose%20of%20this" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [56]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  a prompt radiation start in an infant (\u8805\'5f
12 months old) means they likely entered this trial rather than delaying RT.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 High-Grade Glioma (HGG) and Diffuse Intrinsic Pontine Glioma (DIPG)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : - For }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
supratentorial HGG (glioblastoma/anaplastic astrocytoma)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , the standard of care adopted from adults is concurrent radiotherapy with daily temozolomide followed by adjuvant temozolomide (the \'93Stupp\'94
 regimen). Trials have attempted to improve this: - }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 ACNS0423}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  added }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 lomustine}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627  to adjuvant TMZ}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\
l ":~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [36]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=resection%20extent,Four%20weeks%20after" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [35]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 . - }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 ACNS0822}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  randomized patients to add }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 vorinostat}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627  or }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 bevacizumab}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  versus continue with TMZ alone during RT}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://ncicirb.org/node/2696" \\l ":~:text=A%20Randomized%20Phase%20II%2FIII%20Study,7921%29%20and%20Local" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [49]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.qarc.org/COG/HighGradeGliomas_.pdf" \\
l ":~:text=,%E2%80%93" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [53]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference clues (HGG)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Any mention of }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
temozolomide given during radiation and for 6 cycles after}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  in a child\rquote s glioma treatment indicates a Stupp-based protocol. If additionally }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
lomustine}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  is given (e.g., \'93CCNU every 6 weeks\'94 noted), that identifies ACNS0423}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [36]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . If an antibody like }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 bevacizumab}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  or HDAC inhibitor }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 vorinostat}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 is used upfront with RT, the child likely participated in ACNS0822 (bevacizumab use concurrently with radiation in newly diagnosed glioma is not standard outside of trials)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264" \\l ":~:text=TEMOZOLOMIDE%20,GROUP%20STUDY%20ACNS0822" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [80]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - For }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 DIPG/DMG (brainstem gliomas)}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , standard therapy is radiation alone. Many trials layered experimental therapies: - }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 ACNS0621}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 and PBTC-030: added }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 vorinostat}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (HDAC inhibitor) to radiation}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/" \\l ":~:text=ACNS0822%20was%20a%20feasibility%20and,received%20vorinostat%20230%20mg%2Fm2%2Fdose" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [40]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 PNOC}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627  and PBTC trials: tested various targeted agents (e.g., panobinostat, EGFR or PDGF inhibitors, ONC201, etc.) with radiation. - }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 SJ-DIPG-BATS}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : tested }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 bevacizumab, erlotinib, temozolomide}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  combinations with radiation. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Inference clues (DIPG)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : If a DIPG patient\rquote s record shows an investigational drug given during the 6-week radiation (e.g., \'93patient on vorinostat during RT\'94
 or receiving an EGFR inhibitor like erlotinib with RT), that implies a clinical trial (since outside trials, radiation alone is typical). Combination of }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 radiation + bevacizumab}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627  is a strong sign of the St. Jude DIPG-BATS trial arms}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\
l ":~:text=227%20CPT,radiation%20%2B%20bevacizumab%20%2B%20temozolomide" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [81]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=229%20DIPG,temozolomide%20233%20ETMR%20One" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [82]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 , whereas }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 radiation + panobinostat or pegapanimab (intratumoral)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  would indicate other PBTC/PNOC trials. For example, }{\rtlch\fcs1 
\ab\af31507 \ltrch\fcs0 \b\insrsid3673627 panobinostat/panitumumab with RT}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  would suggest PNOC007, and }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 paxalisib after RT}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627  suggests a PBTC study. Always look for mention of drug names not part of standard chemo \endash  these usually flag a specific trial.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\af31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart Xb7f0dec4df29c4fe663b97e692aeada3ebf5167}{\*\bkmkend Xc9a637d338794c1a78ab22ec21473a54196862e}
\hich\af31506\dbch\af31501\loch\f31506 Brain Tumor Consortium and Institutional Trials}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 Aside from COG and St. Jude, various consortium or single-institution protocols exist: - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 PBTC (Pediatric Brain Tumor Consortium)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  trials often focus on novel agents in refractory tumors. E.g., PBTC-026 (lenalidomide for DIPG), PBTC-027 (cilengitide for DIPG), PBTC-045 (paxalisib for DIPG). These are typically phase I/II with small numbers. - }{\rtlch\fcs1 
\ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Inference}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : If a rare agent is noted (e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 \'93patient on lenalidomide during RT for brainstem glioma\'94}
{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 ), checking PBTC protocols is warranted. The protocol number might even be referenced in records if the patient was on trial. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 
PNOC (Pacific Neuro-Oncology Consortium)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  trials similarly test targeted therapies. E.g., PNOC003 (Everolimus + Bevacizumab in recurrent DIPG)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/" \\l ":~:text=studies,with%20that%20of%20subjects" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [44]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , PNOC013 (Nivolumab combos in DIPG). - }{\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Inference}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Combination of multiple targeted agents (like an immunotherapy drug nivolumab plus another inhibitor) in a child\rquote 
s treatment points to a trial like PNOC013 rather than standard care. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Institutional protocols (e.g., St. Jude SJMB12, SJYC07)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
: These can be identified if one sees unique risk-group nomenclature or therapy elements: - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 St. Jude MB trials}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 stratify by molecular subgroup. If a patient\rquote s plan includes an extremely }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 reduced CSI dose (e.g., 18 Gy)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  for W
NT-medulloblastoma, this was only done on trials like SJMB12}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/full/10.1200/JCO.23.00008" \\
l ":~:text=When%20Can%20We%20Retire%203%2C600,such%20that%20only%20the" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [76]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - Use of }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 smoothened inhibitors (vismodegib)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 for SHH-medulloblastoma in a child would also reflect a trial setting (SJMB12 Stratum S2). - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Multiple risk strata with different therapies}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 mentioned in a summary (like \'93Stratum WNT vs SHH\'94) indicate participation in a trial with molecular stratification (SJMB12 or European PNET5).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\af31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart X73c5be34fa93f329c82f427e3e3061e20384c9f}{\*\bkmkend Xb7f0dec4df29c4fe663b97e692aeada3ebf5167}
\hich\af31506\dbch\af31501\loch\f31506 Neuroblastoma and Other Solid Tumor Protocols}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 While not strictly \'93neuro-oncology,\'94 the list includes neuroblastoma (ANBL) and others, which may appear if CNS metastatic or secondary CNS tumor involvement is present:}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 High-Risk Neuroblastoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ANBL0532, ANBL1531}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : - }{
\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark regimen}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Induction chemo (5\endash 6 cycles of multi-drug therapy including cisplatin, etoposide, cyclophosphamide, doxorubicin) \u8594\'5f
 surgery \u8594\'5f }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 myeloablative chemo with autologous stem cell transplant}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (either single or tandem)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [65]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \u8594\'5f
 radiation to primary site (21 Gy) \u8594\'5f }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 anti-GD2 immunotherapy with isotretinoin}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (maintenance). - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Inference clues}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : The presence of an }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 autologous stem cell transplant}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 and subsequent }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 anti-GD2 immunotherapy (dinutuximab + IL-2 + GM-CSF)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  in a child\rquote 
s treatment plan is a giveaway of a COG high-risk neuroblastoma protocol post-2010. Tandem transplants (two back-to-back transplants) specifically indicate the randomization on ANBL0532 Arm B}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }
}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [65]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  (or certain institutional approaches). If the chart notes 
\'93tandem transplant,\'94 that patient was on the experimental arm for high-risk NBL. Additionally, isotretinoin given as six months of maintenance in a solid tumor context is unique to neuroblastoma therapy}{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [15]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Intermediate-Risk Neuroblastoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \endash  e.g., }{\rtlch\fcs1 \ai\af31507 \ltrch\fcs0 \i\insrsid3673627 COG ANBL0531}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Hallmark}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
: Surgery and moderate chemotherapy (carboplatin, etoposide, cyclophosphamide, doxorubicin) without transplant or immunotherapy}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=154%20ANBL00B1%20155%20ANBL00P1%20156,chemotherapy%2C%20surgery" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [62]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . Number of cycles depends on clinical and biologic risk factors. - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Inference clues}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : If a neuroblastoma patient\rquote s therapy stops after 4\endash 8 chemo cycles with no transplant or immunotherapy, and they\rquote re labeled \'93intermediate risk,
\'94 it\rquote s likely ANBL0531 or similar. The specific drugs (no melphalan, no immunotherapy) differentiate it from high-risk therapy.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Other Solid Tumors}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Wilms Tumor (Kidney)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 
: While not neuro-onc, if seen, Wilms protocols (AREN series) are recognized by vincristine/dactinomycin (2-drug) for low risk, adding doxorubicin for higher stage, and whole abdominal or lung radiation if advanced. For example, a child under 2 with stage
 I Wilms on only vincristine/dactinomycin for 18 weeks (no radiation) was likely on AREN0532}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/" \\l ":~:text=Study%20www,free%20and%20overall%20survival%20outcomes" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [83]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Germ Cell Tumors (CNS)}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : The ACNS1123/0232 trials for CNS germinoma used carboplatin/etoposide chemo \u8594\'5f reduced RT. Clue: 4 cycles of carboplatin-etoposide then only 18 Gy whole-ventricular RT + boost \endash 
 points to ACNS0232}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/10.1200/GO.22.00257" \\l ":~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [84]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 . - }{\rtlch\fcs1 
\ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Retinoblastoma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  or other rare tumors might appear with unique therapy (intra-arterial chemo, etc.), usually referenced by specific trial names in notes (e.g., \'93
CHEERE trial\'94).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s3\ql \li0\ri0\sb160\sa80\keep\keepn\widctlpar\wrapdefault\aspalpha\aspnum\faauto\outlinelevel2\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31503\afs28\alang1025 \ltrch\fcs0 
\fs28\cf19\lang9\langfe1033\loch\af31506\hich\af31506\dbch\af31501\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid3673627 {\*\bkmkstart X0cb37493f6c2928e774baa217c05624c95fed56}{\*\bkmkend X73c5be34fa93f329c82f427e3e3061e20384c9f}
\hich\af31506\dbch\af31501\loch\f31506 Guidelines for Inferring Protocol Enrollment}{\rtlch\fcs1 \af31503 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 When reviewing a pediatric oncology treatment summary, use these guidelines to match it to a protocol:}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 1.\tab}}\pard\plain \ltrpar
\ql \fi-360\li720\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Identify the Diagnosis and Risk Level}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 : Protocols are diagnosis-specific and often risk-adapted. Clues like \'93average-risk medulloblastoma\'94 or \'93high-risk ALL\'94
 in the record will narrow down candidate trials (COG typically, by era).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 2.\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Note Key Therapeutic Components}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 :}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af31507 \ltrch\fcs0 \f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 3.\tab}}\pard\plain \ltrpar
\s17\ql \fi-360\li720\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 The }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 chemotherapy agents and their combinations}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  can be signature identifiers. For instance:}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}\pard \ltrpar
\s17\ql \fi-360\li1440\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls3\ilvl1\adjustright\rin0\lin1440\itap0 {\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Nelarabine}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  \u8594\'5f
 T-ALL trials (AALL0434)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric" \\
l ":~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [3]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Carboplatin during radiation}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  \u8594\'5f high-risk MB trials (ACNS0332)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\
l ":~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [11]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Isotretinoin}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 in a brain tumor context \u8594\'5f ACNS0332 (medullo) or neuroblastoma maintenance.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Anti-GD2 antibody}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  \u8594\'5f neuroblastoma high-risk protocol (modern era).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Thiotepa}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  and }{
\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 autologous transplant}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  for a brain tumor under age 3 \u8594\'5f Head Start or ACNS0334.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Temozolomide + Lomustine}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  for upfront glioma \u8594\'5f ACNS0423}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\
l ":~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [36]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Bevacizumab + irinotecan + temozolomide}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627  in recurrent MB \u8594\'5f ACNS0821 TIB arm}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/33844469/" \\
l ":~:text=NIH%20pubmed,The%20combination%20was%20relatively" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [48]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 4.\tab}}\pard \ltrpar
\s17\ql \fi-360\li720\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 {\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Radiation fields and doses}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 :}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}\pard \ltrpar
\s17\ql \fi-360\li1440\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls4\ilvl1\adjustright\rin0\lin1440\itap0 {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
CSI dose 23.4 vs 36 Gy distinguishes standard vs high-risk medulloblastoma protocols}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\
l ":~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [85]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
The use of CSI at all in a child <3 suggests recurrence or protocol deviation, since standard trials avoid it (unless on a relapse trial or AT/RT at age ~2 where CSI might be considered like ACNS0333 Arm II for >12m old}{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=%283D,6%20weeks" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [26]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 ).}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
Whole ventricular irradiation of 18 Gy followed by boost implies a germinoma chemo/RT trial (ACNS0232)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/10.1200/GO.22.00257" \\
l ":~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [84]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 .}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
Proton vs photon mention: some trials (PNOC or SJ) evaluate proton therapy differences (e.g., ACNS0831 had an objective regarding proton vs photon outcomes}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=therapy%20contributes%20to%20neurobehavioral%20morbidity,therapy%20followed%20by%20observation%20alone" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [86]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 ).}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 5.\tab}}\pard\plain \ltrpar
\ql \fi-360\li720\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Surgical timing and additional procedures}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 :}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af2 \ltrch\fcs0 \f2\lang9\langfe1033\langnp9 \hich\af2\dbch\af31506\loch\f2 o\tab}}\pard\plain \ltrpar
\s17\ql \fi-360\li1440\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls5\ilvl1\adjustright\rin0\lin1440\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 \'93Second-look surgery\'94 after initial chemo \endash  common in protocols like ACNS0333 (AT/RT)}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=After%20completion%20of%20induction%20therapy%2C,to%201%20of%202%20arm" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [87]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 or ACNS0334 (some patients had second resection after induction). If noted, it shows the protocol\rquote s strategy (improving resection after chemo).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 6.\tab}}\pard\plain \ltrpar
\ql \fi-360\li720\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 Compare Treatment Timing and Sequence}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 :}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \s17 \rtlch\fcs1 \af31507 \ltrch\fcs0 \f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 7.\tab}}\pard\plain \ltrpar
\s17\ql \fi-360\li720\ri0\sb36\sa36\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 Protocols have defined phase timing. For example, ACNS0334 specifies }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 3 induction cycles, then within 6 weeks proceed to transplant}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\l ":~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [74]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 . If you see long gaps or extra cycles, the patient may have gone off-protocol or switched.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \af31507 \ltrch\fcs0 \f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 8.\tab}}\pard\plain \ltrpar
\ql \fi-360\li720\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\ls2\adjustright\rin0\lin720\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 Maintenance therapy presence or absence is informative: Ependymoma standard has none, so if given, it\rquote s a trial (ACNS0831). ALL always has maintenance (2+ years); if a leukemic patient doesn\rquote 
t, they were not on an established protocol (or data is incomplete).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 9.\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Look for Explicit Mentions}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : Sometimes the protocol number or name is directly referenced in clinic notes or discharge summaries (e.g., \'93treated per ACNS0331\'94). The provided table and references can then be used to confirm details of that protocol
\rquote s regimen.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par {\listtext\pard\plain\ltrpar \rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\f31506\lang9\langfe1033\langnp9 \hich\af31506\dbch\af31506\loch\f31506 10.\tab}}{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 Cross-Reference with Era}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 : Trials open/close in specific years. If a therapy was given in, say, 2010 for average-risk medulloblastoma, ACNS0331 (opened ~2004\endash 
2012) is likely; by 2018, ACNS0331 was closed and a successor (ACNS1422 or SJMB12 at St. Jude) might be in use. Use dates and the institution to infer if it was a COG protocol or an institutional one.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }\pard\plain \ltrpar\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 By leveraging the above reference table and recognizing these patterns, an LLM or clinician can infer with high confidence which protocol a patient\rquote s treatment followed. Always verify against the patient\rquote 
s eligibility (age, risk) and any mention of consent to a trial. The combination of }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 treatment components}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 
\b\insrsid3673627 structure}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , and }{\rtlch\fcs1 \ab\af31507 \ltrch\fcs0 \b\insrsid3673627 context}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  provides a \'93fingerprint\'94
 for each protocol. When uncertain, one should consult protocol publications or clinical trial registries (ClinicalTrials.gov, NCI PDQ\'ae) using key trial identifiers (which are provided in the table where available, e.g., NCT numbers}
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [6]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2695" \\l ":~:text=Temozolomide%20with%20Irinotecan%20versus%20Temozolomide%3B,A%20Groupwide%20Phase%20II%20Study" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [43]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 ).}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \ab\af31507 
\ltrch\fcs0 \b\insrsid3673627 Sources:}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  The compiled data above is drawn from Children\rquote s Oncology Group clinical trial protocols and publications}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=ABSTRACT%20Medulloblastoma%20is%20the%20most,randomly%20assigned%20to%20receive%20carboplatin" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [9]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt 
{\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [6]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 , St. Jude trial reports}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [85]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
, and other authoritative sources including ClinicalTrials.gov and NCI summaries}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" 
\\l ":~:text=ARM%20I%3A%20Patients%20receive%20vincristine,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
[27]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\
l ":~:text=I,VCEC" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [57]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 . Specific citations are provided in the table for detailed verification of dosing, sequence, and outcomes. These references include peer-reviewed articles (e.g., JCO, Neuro-Oncology), which report the trials\rquote 
 methods and results, as well as protocol documents and summaries from clinical trial registries.}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\pard\plain \ltrpar\ql \li0\ri0\sa200\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\lang1024\langfe1024\noproof\insrsid5777772 {\*\bkmkend Xf38c977c61f036247de3444d788f9a19e1e08b1}{\*\bkmkend content}{\*\bkmkend reference-guide-and-inference-guidelines}{\*\bkmkend X0cb37493f6c2928e774baa217c05624c95fed56}
{\pict{\*\picprop\shplid1026{\sp{\sn shapeType}{\sv 1}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fFilled}{\sv 1}}{\sp{\sn alignHR}{\sv 1}}{\sp{\sn dxHeightHR}{\sv 1}}{\sp{\sn dxWidthHR}{\sv 9360}}{\sp{\sn fStandardHR}{\sv 1}}
{\sp{\sn fHorizRule}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex216\picscaley1\piccropl0\piccropr0\piccropt0\piccropb0\picw7620\pich7620\picwgoal4320\pichgoal4320\wmetafile8}}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}
{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\pard\plain \ltrpar
\s16\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\*\bkmkstart citations}
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161" \\l ":~:text=,have%20other%20tests%20as%20needed" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [1]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161" \\l ":~:text=Eligibility%3A" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [2]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  NIH Clinical Center: Search the Studies}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }\pard\plain \ltrpar\s15\ql \li0\ri0\sb180\sa180\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31507\afs24\alang1025 \ltrch\fcs0 \f31506\fs24\lang9\langfe1033\cgrid\langnp9\langfenp1033 {\field\fldedit{\*\fldinst 
{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2011-C-0161}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric" \\
l ":~:text=COG%20AALL0434%20protocol%20%C2%B7%20Induction%2C,Cytarabine%2C%20Mercaptopurine%2C%20Nelarabine%2C%20Pegaspargase%2C%20Vincristine" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [3]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  T-cell acute lymphoblastic leukemia, pediatric | HemOnc.org}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://hemonc.org/wiki/T-cell_acute_lymphoblastic_leukemia,_pediatric}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/" \\l ":~:text=Table%208%2C%20Treatment%20Details%20in,risk%20participants%20only" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [4]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  Table 8, Treatment Details in COG AALL0434 - Nelarabine (Atriance)}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.ncbi.nlm.nih.gov/books/NBK599994/table/tr826986112990307_ch01_t08/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\
l ":~:text=cycles%20of%20maintenance%20chemotherapy%20with,isotretinoin%20during%20and%20following%20maintenance" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
[5]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=Age%20at%20enrollment%2C%20y%20Median,7" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [10]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=Efficacy%20of%20Carboplatin%20and%20Isotretinoin,risk%20group%203%20medulloblastoma" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [13]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=Findings%C2%A0%20In%20this%20randomized%20clinical,risk%20group%203%20medulloblastoma" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [14]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\l ":~:text=chemotherapy%20before%20radiotherapy%20as%20compared,279" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [77]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children\rquote s Oncology Group | Neuro-oncology | JAMA Oncology | JAMA Network}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://jamanetwork.com/journals/jamaoncology/fullarticle/2782033}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=Methods%3A%20%20ACNS0331%20%28ClinicalTrials,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [6]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=years,ototoxicity%20were%20monitored%20over%20time" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [8]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\l ":~:text=Children%27s%20Oncology%20Group%20Phase%20III,risk%20MB%20to%20receive" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [85]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma - PubMed}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34110925/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pubmed.ncbi.nlm.nih.gov/34110925/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=53%20%22ACNS0331%3A%20Arm%20V%20%288,years%20of%20age%2C%20SDCSI%2C%20PFRT" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [7]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=154%20ANBL00B1%20155%20ANBL00P1%20156,chemotherapy%2C%20surgery" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [62]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=match%20at%20L550%20157%20,enrolled%20on%20intermediate%20risk%20trial" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [63]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [64]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=160%20ANBL0532%3A%20Consolidation%20Arm%20A%3A,Arm%20B%3A%20tandem%20myeloablative%20consolidation" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [65]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=164%20,ANHL0131%3A%20Experimental%3A%20Consolidation%20with%20Vinblastine" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [67]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=562%20Head%20Start%20II%3A%20induction,96%3A%20Stratum%20I%3A%20Option" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [73]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=454%20SJMB03%20455%20SJMB03%3A%20Stratum,458%20SJMB12%3A%20Stratum%20N2%3A%20Intermediate" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [75]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=200%20CCG,A9952%3A%20Regimen%20A%20%28CV%20Chemotherapy" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [79]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=227%20CPT,radiation%20%2B%20bevacizumab%20%2B%20temozolomide" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [81]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\l ":~:text=229%20DIPG,temozolomide%20233%20ETMR%20One" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 [82]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  CBTN _ REDCap_treatment.pdf}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "file://file_000000008ddc71f78c8e4acd437cfe6c" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 file://file_000000008ddc71f78c8e4acd437cfe6c}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\
l ":~:text=ABSTRACT%20Medulloblastoma%20is%20the%20most,randomly%20assigned%20to%20receive%20carboplatin" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [9]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=medulloblastoma%20and%20it%20has%20been,ACNS0332%20previously%20included%20supratentorial" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [11]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=this%20study%20is%20to%20determine,99701" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [12]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=a%20second%20randomization%20to%20assess,ACNS0332%20has%20been%20suspended%20effective" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [15]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=Note%3A%20Enrollment%20to%20Regimen%20C,The%20Study%20Committee" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [17]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=C%20and%20D%29,risk" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [18]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=receive%20carboplatin%20radiosensitization,Correlative%20biology" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [70]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\l ":~:text=demonstrated%20that%20it%20was%20feasible,ACNS0332%20previously%20included%20supratentorial" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [72]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 cdn.clinicaltrials.gov}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://cdn.clinicaltrials.gov/large-docs/27/NCT00392327/Prot_SAP_000.pdf}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/noa/article/7/1/vdaf054/8051863" \\l ":~:text=,risk%20medulloblastoma%20therapy.%20Isotretinoin" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [16]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 A secondary analysis of the Children's Oncology Group ACNS0332 ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/noa/article/7/1/vdaf054/8051863" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 https://academic.oup.com/noa/article/7/1/vdaf054/8051863}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\
l ":~:text=INDUCTION%20THERAPY%20AND%20STEM%20CELL,4%20days" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [19]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=hours%20after%20the%20start%20of,6%20CD34%2B%20cells%2Fkg%20have" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [20]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\
l ":~:text=CONSOLIDATION%20THERAPY%20AND%20STEM%20CELL,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [21]}
}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=dose%20carboplatin%20IV%20over%204,disease%20progression%20or%20unacceptable%20toxicity" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [22]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\
l ":~:text=RADIATION%20THERAPY%3A%20Patients%20undergo%203,6%20weeks" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [23]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=ARM%20I%20,any%20primary%20site%20or%20age" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [24]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=ARM%20II%20,rescue%20as%20in%20Arm%20I" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [25]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\l ":~:text=%283D,6%20weeks" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [26]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\
l ":~:text=After%20completion%20of%20induction%20therapy%2C,to%201%20of%202%20arm" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [87]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://ctv.veeva.com/study/combination-chemotherapy-radiation-therapy-and-an-autologous-peripheral-blood-stem-cell-transplant}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\
l ":~:text=ARM%20I%3A%20Patients%20receive%20vincristine,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
[27]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\l ":~:text=and%202%3B%20cisplatin%20IV%20over,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [28]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\l ":~:text=OUTLINE%3A%20Patients%20are%20randomized%20to,1%20of%202%20treatment%20arms" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [30]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\
l ":~:text=ARM%20II%3A%20Patients%20receive%20vincristine,for%203%20courses%20in%20the" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [31]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\l ":~:text=CONSOLIDATION%20THERAPY%3A%20Beginning%20no%20more,disease%20progression%20or%20unacceptable%20toxicity" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [74]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma - NCI}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt 
{\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT00336024}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1878747923001307" \\l ":~:text=,with%20randomization%20of%20added" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [29]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Medulloblastoma in the Modern Era: Review of Contemporary Trials ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1878747923001307" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.sciencedirect.com/science/article/pii/S1878747923001307}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409" \\
l ":~:text=Phase%203%20randomized%20trial%20of,CCG9970316%20intensive%20chemotherapy%20backbone" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [32]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409" \\l ":~:text=The%20primary%20objective%20of%20ACNS0334,CCG9970316%20intensive%20chemotherapy%20backbone" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [33]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Phase 3 randomized trial of high-dose methotrexate for young ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf132/8158409}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=match%20at%20L447%20resection%20extent,Four%20weeks%20after" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [34]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=resection%20extent,Four%20weeks%20after" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [35]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=concurrent%20temozolomide,2%7D%2Fday%20%C3%975%20every%206%20weeks" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [36]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=designed%20to%20determine%20whether%20lomustine,DNA" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [37]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=participants%20treated%20with%20adjuvant%20temozolomide,comparison%20by%20resection%20extent%2C%20the" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [38]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=radiation%20with%20adjuvant%20and%20concurrent,based%20therapies.1" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [39]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\l ":~:text=temozolomide%20to%20radiotherapy%20significantly%20increased,The%20study%20found" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [52]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
  Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study - PMC }{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pmc.ncbi.nlm.nih.gov/articles/PMC5035517/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/" \\l ":~:text=ACNS0822%20was%20a%20feasibility%20and,received%20vorinostat%20230%20mg%2Fm2%2Fdose" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [40]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 TR-14: A FEASIBILITY AND RANDOMIZED PHASE II STUDY ... - NIH}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pmc.ncbi.nlm.nih.gov/articles/PMC4482948/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40487589/" \\l ":~:text=,TIB%20cycle%20includes%20oral" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [41]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40487589/" \\l ":~:text=Children%20with%20medulloblastoma%20treated%20with,TIB%20cycle%20includes%20oral" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [46]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Children with medulloblastoma treated with modified ACNS0821 ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40487589/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pubmed.ncbi.nlm.nih.gov/40487589/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://link.springer.com/article/10.1007/s40278-025-88222-5" \\l ":~:text=Case%201%3A%20A%20child%20with,mg%2Fm2per%20day%20for%20the" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [42]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Bevacizumab/Irinotecan/Temozolomide | Reactions Weekly}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://link.springer.com/article/10.1007/s40278-025-88222-5" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 https://link.springer.com/article/10.1007/s40278-025-88222-5}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2695" \\l ":~:text=Temozolomide%20with%20Irinotecan%20versus%20Temozolomide%3B,A%20Groupwide%20Phase%20II%20Study" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [43]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2695" \\l ":~:text=ACNS0821,IND%23%207921%29%20for%20Recurrent%2FRefractory" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [45]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  ACNS0821 | NCICIRB}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2695" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://ncicirb.org/node/2695}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/" \\l ":~:text=studies,with%20that%20of%20subjects" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [44]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 ACNS0821 - Clinical Research Studies - All IN for Health}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://research-studies.allinforhealth.info/us/en/listing/3503/acns0821-temozolomide-with/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/33844469/" \\l ":~:text=NIH%20pubmed,The%20combination%20was%20relatively" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [47]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/33844469/" \\l ":~:text=NIH%20pubmed,The%20combination%20was%20relatively" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [48]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  Report of a COG randomized Phase II screening trial - PubMed - NIH}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/33844469/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pubmed.ncbi.nlm.nih.gov/33844469/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2696" \\l ":~:text=A%20Randomized%20Phase%20II%2FIII%20Study,7921%29%20and%20Local" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [49]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  ACNS0822 | NCICIRB}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ncicirb.org/node/2696" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://ncicirb.org/node/2696}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_
CHILDRE" \\l ":~:text=The%20COG%20ACNS0822%20trial%20compared,conventional%20RT%20followed%20by" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [50]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  tr-14 * a feasibility and randomized phase ii study of vorinostat ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_
CHILDRE" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
https://www.researchgate.net/publication/276080467_TR-14_A_FEASIBILITY_AND_RANDOMIZED_PHASE_II_STUDY_OF_VORINOSTAT_BEVACIZUMAB_OR_TEMOZOLOMIDE_DURING_RADIATION_FOLLOWED_BY_MAINTENANCE_CHEMOTHERAPY_IN_NEWLY-DIAGNOSED_PEDIATRIC_HIGH-GRADE_GLIOMA_CHILDRE}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/38596718/" \\l ":~:text=Vorinostat%2C%20temozolomide%20or%20bevacizumab%20with,children%20with%20newly%20diagnosed%20HGG" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [51]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/38596718/" \\
l ":~:text=Vorinostat%2C%20temozolomide%20or%20bevacizumab%20with,children%20with%20newly%20diagnosed%20HGG" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [54]}
}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  Vorinostat, temozolomide or bevacizumab with irradiation and ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/38596718/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pubmed.ncbi.nlm.nih.gov/38596718/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.qarc.org/COG/HighGradeGliomas_.pdf" \\l ":~:text=,%E2%80%93" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [53]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  [PDF] Pediatric High Grade Glioma}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.qarc.org/COG/HighGradeGliomas_.pdf" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://www.qarc.org/COG/HighGradeGliomas_.pdf}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html" \\l ":~:text=,radiation%20therapy%20in%20treating%20glioma" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [55]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Vorinostat, Temozolomide, or Bevacizumab in Combination With ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 https://clinicaltrials.stanford.edu/trials/v/NCT01236560.html}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S245210942100049X" \\l ":~:text=Effect%20of%20Postoperative%20Radiation%20Therapy,The%20purpose%20of%20this" \\h}{
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [56]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627  Effect of Postoperative Radiation Therapy Timing on Survival in ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S245210942100049X" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.sciencedirect.com/science/article/pii/S245210942100049X}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=I,VCEC" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [57]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=children%20with%20completely%20resected%20ependymoma,VCEC" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [58]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=The%20primary%20aim%20of%20this,One%20arm%20studied" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [59]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\l ":~:text=The%20primary%20aim%20of%20this,One%20arm%20studied" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [60]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }{\field\fldedit{\*\fldinst {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\
l ":~:text=therapy%20contributes%20to%20neurobehavioral%20morbidity,therapy%20followed%20by%20observation%20alone" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 [86]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Ependymoma - NCI}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt 
{\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01096368}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy" \\
l ":~:text=Should%20adjuvant%20maintenance%20chemotherapy%20be,SIOP%20Ependymoma%20trial%20in%20Europe" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [61]}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  Should adjuvant maintenance chemotherapy be provided to}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
https://www.themednet.org/should-adjuvant-maintenance-chemotherapy-be-provided-to-children-with-anaplastic-ependymoma-following-radiation-therapy}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/" \\
l ":~:text=,risk%20Group%203%20medulloblastoma" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [66]}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  The Largest High-Risk Medulloblastoma Trial Makes Monumental ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 
https://www.seattlechildrens.org/media/press-releases/the-largest-high-risk-medulloblastoma-trial-makes-monumental-strides-forward-for-cancer-research-increases-survival-in-children-by-19-percent/}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/" \\l ":~:text=Study%20www,free%20and%20overall%20survival%20outcomes" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [68]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627  }
{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/" \\l ":~:text=Study%20www,free%20and%20overall%20survival%20outcomes" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [83]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Promising Results From Children's Oncology Group AALL0434 Study}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://www.hematologyadvisor.com/news/cog-produces-successful-t-all-results/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 

\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32552472/" \\l ":~:text=Results%20From%20Children%27s%20Oncology%20Group,LL" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
{\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [69]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Results From Children's Oncology Group AALL0434 - PubMed - NIH}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32552472/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://pubmed.ncbi.nlm.nih.gov/32552472/}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/" \\l ":~:text=High,1185.%20doi%3A%2010.1200%2FJCO" \\h}{\rtlch\fcs1 
\af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [71]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 High-dose chemotherapy with autologous hematopoietic stem cell ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
HYPERLINK "https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}
}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://cttjournal.com/en/archive/tom-10-nomer-1/klinicheskie-raboty/vysokodoznaya-polikhimioterapiya-s-autologichnoy-transplantatsiey-gemopoeticheskikh-stvolovykh-kleto/}}}
\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/full/10.1200/JCO.23.00008" \\l ":~:text=When%20Can%20We%20Retire%203%2C600,such%20that%20only%20the" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [76]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 When Can We Retire 3,600 cGy Craniospinal Irradiation in ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/full/10.1200/JCO.23.00008" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 
\ltrch\fcs0 \cs51\cf22\insrsid3673627 https://ascopubs.org/doi/full/10.1200/JCO.23.00008}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf" \\l ":~:text=,volume%20in%20the%20ongoing" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [78]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 [PDF] Pediatric Radiation Oncology}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 http://ndl.ethernet.edu.et/bitstream/123456789/12832/1/Edward%20C.%20Halperin.pdf}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264" \\l ":~:text=TEMOZOLOMIDE%20,GROUP%20STUDY%20ACNS0822" \\h}{\rtlch\fcs1 \af31507 
\ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [80]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 tr-14 a feasibility and randomized phase ii study of vorinostat ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {
\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 https://academic.oup.com/neuro-oncology/article-abstract/17/suppl_3/iii39/1042264}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/10.1200/GO.22.00257" \\l ":~:text=Outcome%20of%20Children%20and%20Adolescents,WVFI%29%20and" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 
\insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 \cs51\cf22\insrsid3673627 [84]}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 
 Outcome of Children and Adolescents With Primary Intracranial ...}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 
\par }{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 HYPERLINK "https://ascopubs.org/doi/10.1200/GO.22.00257" \\h}{\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid3673627 {\*\datafield }}}{\fldrslt {\rtlch\fcs1 \af31507 \ltrch\fcs0 
\cs51\cf22\insrsid3673627 https://ascopubs.org/doi/10.1200/GO.22.00257}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj\sftnrestart {\rtlch\fcs1 \af31507 \ltrch\fcs0 \insrsid878590 {\*\bkmkend citations}
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b03041400060008000000210094a9528694070000c7200000160000007468656d652f7468656d652f
7468656d65312e786d6cec595f8b1bc9117f0fe43b0cf32e6b66248da4c5f2a1bfdeb3776d63c90ef7d82bb566dadb333d4cb7762d8e83e07bca4b207077e421
0779cb430839c8418ebce4c3186c92cb874875cf68d42db5bc7f30c184dd7dd1b47e55fd9baaeaaa52f5fdcf5e27d4b9c039272cedb9fe3dcf75703a670b9246
3df7c56c52ebb80e17285d20ca52dc73d798bb9f3df8e52feea32311e3043b209ff223d4736321b2a37a9dcf6119f17b2cc3297cb7647982043ce6517d91a34b
d09bd07ae079613d4124759d1425a0f6e97249e6d8994995ee838df23185c75470b930a7f954aac68684c22ece7d89e06b3ea4b9738168cf857d16ec72865f0b
d7a1880bf8a2e77aeacfad3fb85f4747a51015076435b989fa2be54a81c579a0f6cca3b36a536f1c749a7ea55f01a8d8c78d3bf2bfd2a700683e87372db8e83a
fd56e8758212ab818a8f16ddddb6df30f19afec61e67bf1b0e82a6a15f810afdcd3dbc37e98e472d03af4005beb587ef7bc1a0db30f00a54e0c33d7c73dc6f07
6303af403125e9f93e3a6c773a6189ae204b468fadf06e187aed5109dfa2201aaae8925b2c592a0ec55a825eb17c020009a44890d411eb0c2fd11ca2b89f09c6
9d11e119456bd7c950ca382c7b81ef43e835bda0fa571647471869d2921730e17b4b928fc3e739c944cf7d045a5d0df2eea79fdebef9f1ed9bbfbffdfaebb76f
feea9c902816852a43ee18a5912ef7f39f7ef79fef7fedfcfb6f7ffcf99b6fed78aee3dfffe537effff1cf0fa987a3b635c5bbef7e78ffe30fef7effdb7ffdf9
1b8bf67e8ece74f88c24983b4ff0a5f39c25f082ca14267f7c96df4c621623a24bf4d388a314c95d2cfac72236d04fd688220b6e804d3bbecc21d5d8800f57af
0cc2d3385f0962d1f8384e0ce0296374c072ab151ecbbd3433cf566964df3c5fe9b8e7085dd8f61ea2d4f0f27895418e253695c3181b349f51940a14e1140b47
7ec7ce31b6bcdd178418763d25f39c71b614ce17c419206235c98c9c19d1b4153a2609f8656d2308fe366c73fad219306a7beb11be3091703610b5909f616a98
f1215a0994d854ce504275839f2011db484ed7f95cc78db9004f47983267bcc09cdb649ee6f0be9ad31f23c86e56b79fd27562227341ce6d3a4f10633a72c4ce
87314a321b764ad258c77ececf214491f38c091bfc949927443e831f507ad0dd2f0936dc7d75367801594ea7b40d10f9cd2ab7f8f2216646fc4ed77489b02dd5
f4f3c448b1fd9c58a363b08a8cd03ec198a24bb4c0d879f1b985c1806586cdb7a41fc590558eb12db01e213356e5738a39f44ab2b9d9cf9327841b213bc5113b
c0e774bd9378d6284d507e48f313f0ba6ef3f1590e87d142e1299d9febc027047a408817ab519e72d0a105f741adcf62641430f9ccedf1bace0dff5de78cc1b9
7c65d0b8c6b904197c631948ecbacc076d3343d4d8601b3033449c135bba0511c3fd5b11595c95d8ca2ab7340fedd60dd01d194d4f42d22b3aa0ff5de703fdc5
bb3f7c6f09c18fd3edd8151ba9ea867dcea15472bcd3dd1cc2edf63443962fc8a7dfd28cd02a7d86a18aece7abbb8ee6aea371ffef3b9a43e7f9ae8f39d46ddc
f5312ef417777d4c395af9387dccb67581ae468e178a318f1afa2407673e4b42e954ac293ee16aecc3e1d7cc62028b524ecd3b713503cc62f828cb1c6c60e0a2
1c29192767e25744c4d31865301bf25da924e2a5ea883b19e3303252cb56dd124f57c9295b14a34e355bf28acaca91d8ae7b2d183a15eb30a612053a6c978b92
9f9aa7025fc5365263d60d01297b1312da6626898685447bb37805093935fb382cba16161da97ee3aa3d5300b5ca2bf073db811fe93db7d594846046cee7d09a
2fa49f0a576fbcab9cf9313d7dc8984604c058b1781318ca579eee4aae075f4fbe5d116ad7f0b4414239a5082b9384b28c6af0780c3f82cbe894abd7a171535f
77b72e35e84953a8fd20beb734da9d0fb1b8adaf416e3737d054cf1434752e7b6ed86841c8cc51d673973032868f4906b1c3e52f2e4423b877998bbc38f0b7c9
2c59cec508f1b830b84a3a857b122270ee5092f45cf9fa951b68aa7288e2e60790103e59725d482b9f1a3970bae964bc5ce2b9d0ddaead484b178f90e18b5c61
fd5689df1e2c25d90adc3d8d1797ce195de5cf118458abed4b032e08879b03bfb0e682c0555895c8b6f1b75398cae4afdf45a9182ad611cd625456143d991770
554f2a3aeaa9b281f654be33185433495908cf22596075a31ad5b42a5d05878355f76a2169392d696e6ba6915564d5b4673163874d19d8b1e5ed8abcc66a6362
c8697a852f52f76ecaed6e72dd4e9f505509307865bfdb957e8dda7633839a64bc9f8665ce2e57cddab179c12ba85da74868593fdca8ddb15b5523acdbc1e2ad
2a3fc8ed462d2c2d377da5b2b4ba33d7afb5d9d92b481e23e872575470e54a98ebe608bab2a9ea498ab40147e4b5288f067c725639e9b95f7aad7e7318b48635
afd31ad79a8da657ebb4fa8d5abfd56af8e396ef8d06c1575058449cf8ade2be7e02d717745ddedaabf5bd9bfb647343736fce923a5337f375455cdddcfbc1e1
9b7b8740d2f93218fbcda01f0c6bc3911fd69ac128ac75da8d7e6d1884a3a00f293d9cf4bf729d0b05f607a3d164d20a6ae110704dafdfaaf5078d612dec8c07
c1c41f37471e80cbccf91afa6fb0e9c616f051f17af05f000000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468656d
652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4350d
363f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d26245228
2e3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe514173d9
850528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c0200001300000000000000000000
000000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b000000000000000000
00000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c00000000000000000000000000190200
007468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d001400060008000000210094a9528694070000c720000016000000000000
00000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b010000270000
00000000000000000000009e0a00007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d010000990b00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax376\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef0{\lsdlockedexcept \lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Normal Table;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 1;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Simple 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Classic 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Colorful 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 3;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Columns 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 6;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 7;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Grid 8;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 5;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 6;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 7;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table List 8;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table 3D effects 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Contemporary;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Elegant;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Professional;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Subtle 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Subtle 2;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 1;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 2;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Web 3;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Table Theme;\lsdpriority49 \lsdlocked0 Grid Table 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;
\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Mention;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Smart Hyperlink;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Hashtag;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Unresolved Mention;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Smart Link;}}{\*\datastore }}